# Stephen G. Swisher

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/stephen-g-swisher/

## Facts

| Field | Value |
| --- | --- |
| Citations | 47,433 |
| Field | Esophageal Cancer Research and Treatment |
| h-index | 111 |
| i10-index | 457 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5076621000 |
| ORCID iD | https://orcid.org/0000-0002-3080-1920 |
| Works | 965 |

## Researcher papers

- [Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study](https://scholariq.org/papers/local-consolidative-therapy-vs-maintenance-therapy-or-observation-for-patients/)
- [Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study](https://scholariq.org/papers/local-consolidative-therapy-versus-maintenance-therapy-or-observation-for/)
- [Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing](https://scholariq.org/papers/intratumor-heterogeneity-in-localized-lung-adenocarcinomas-delineated-by/)
- [Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities](https://scholariq.org/papers/patterns-of-transcription-factor-programs-and-immune-pathway-activation-define/)
- [Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial](https://scholariq.org/papers/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-operable-non-small-cell/)
- [Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer](https://scholariq.org/papers/adenovirus-mediated-p53-gene-transfer-in-advanced-non-small-cell-lung-cancer/)
- [IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy](https://scholariq.org/papers/iaslc-multidisciplinary-recommendations-for-pathologic-assessment-of-lung-cancer/)
- [Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i> -Mutant NSCLC](https://scholariq.org/papers/landscape-of-egfr-dependent-and-independent-resistance-mechanisms-to-osimertinib/)
- [Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer](https://scholariq.org/papers/single-cell-analyses-reveal-increased-intratumoral-heterogeneity-after-the-onset/)
- [Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer](https://scholariq.org/papers/effect-of-operative-volume-on-morbidity-mortality-and-hospital-use-after/)
- [Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer](https://scholariq.org/papers/oncogene-specific-differences-in-tumor-mutational-burden-pd-l1-expression-and/)
- [Relationship Between Tumor Size and Survival in Non–Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry](https://scholariq.org/papers/relationship-between-tumor-size-and-survival-in-non-small-cell-lung-cancer-nsclc/)

## Researcher topics

- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.